FSD Pharma Inc.

CNSX:HUGE Stock Report

Market Cap: CA$25.7m

FSD Pharma Management

Management criteria checks 2/4

FSD Pharma's CEO is Zeeshan Saeed, appointed in Jul 2021, has a tenure of 2.75 years. total yearly compensation is $599.87K, comprised of 37.1% salary and 62.9% bonuses, including company stock and options. directly owns 5.59% of the company’s shares, worth CA$1.43M. The average tenure of the management team and the board of directors is 2.8 years and 2.6 years respectively.

Key information

Zeeshan Saeed

Chief executive officer

US$599.9k

Total compensation

CEO salary percentage37.1%
CEO tenure2.8yrs
CEO ownership5.6%
Management average tenure2.8yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Apr 13
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Dec 17
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

Aug 25
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

Feb 13
How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

CEO Compensation Analysis

How has Zeeshan Saeed's remuneration changed compared to FSD Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$600kUS$223k

-US$18m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$774kUS$239k

-US$27m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$1mUS$225k

-US$34m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$899kUS$212k

-US$28m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$249k

-US$34m

Sep 30 2019n/an/a

-US$38m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$503kUS$183k

-US$17m

Compensation vs Market: Zeeshan's total compensation ($USD599.87K) is above average for companies of similar size in the Canadian market ($USD175.48K).

Compensation vs Earnings: Zeeshan's compensation has been consistent with company performance over the past year.

CEO

Zeeshan Saeed (53 yo)

2.8yrs

Tenure

US$599,873

Compensation

Mr. Zeeshan Saeed serves as Executive Co-Chairman at FSD Pharma Inc. since May 24, 2018 and serves as its President since July 27, 2021 and Chief Executive Officer since June 29, 2023. He serves as Co-Chai...

Leadership Team

NamePositionTenureCompensationOwnership
Zeeshan Saeed
Founder2.8yrsUS$599.87k5.59%
$ 1.4m
Anthony Durkacz
Founder & Executive Co-Chairman5.8yrsUS$599.87k2.54%
$ 651.0k
Nathan Coyle
Chief Financial Officer2.9yrsUS$178.21k0.0062%
$ 1.6k
Donal Carroll
Chief Operating Officer2.7yrsUS$602.87k2.43%
$ 622.9k
Lakshmi Kotra
CEO of Lucid & Director2.6yrsUS$521.97k3.55%
$ 910.2k
Maryann Adesso
Corporate Secretaryno datano datano data
Randell Mack
President of FSD BioSciences3.1yrsno datano data
Andrzej Chruscinski
Vice President of Clinical & Scientific Affairs of Lucidno dataUS$110.30k0%
$ 0
Kevin Cassidy
Vice President of Quality-Lucidno dataUS$144.82kno data

2.8yrs

Average Tenure

47yo

Average Age

Experienced Management: HUGE's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zeeshan Saeed
Founder2.9yrsUS$599.87k5.59%
$ 1.4m
Anthony Durkacz
Founder & Executive Co-Chairman5.8yrsUS$599.87k2.54%
$ 651.0k
Lakshmi Kotra
CEO of Lucid & Director1.4yrsUS$521.97k3.55%
$ 910.2k
Daniele Piomelli
Member of Research & Clinical Advisory Board2.3yrsno datano data
Eleanor Fish
Member of Research & Clinical Advisory Board2.4yrsno datano data
Hance Clarke
Member of Research & Clinical Advisory Board2.6yrsno datano data
Adnan Bashir
Independent Director2.8yrsUS$139.37k0.023%
$ 6.0k
Peter Stys
Member of Research & Clinical Advisory Board2.6yrsno datano data
Shannon Dunn
Member of Research & Clinical Advisory Board2.6yrsno datano data
Albert Wong
Member of Research & Clinical Advisory Board2.6yrsno datano data
Joga Gobburu
Member of Regulatory Advisory Board2.4yrsno datano data
Mary Melnyk
Member of Regulatory Advisory Board2.4yrsno datano data

2.6yrs

Average Tenure

52.5yo

Average Age

Experienced Board: HUGE's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.